Patents by Inventor Hans Allgeier

Hans Allgeier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of Protein Kinases
    Publication number: 20150038516
    Abstract: Compounds of general Formula I: wherein R1, R2, R3, x, A and Ra are as defined herein are inhibitors of cyclin-dependent kinases and are useful for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.
    Type: Application
    Filed: May 5, 2014
    Publication date: February 5, 2015
    Applicant: AstraZeneca AB
    Inventors: Hans Allgeier, Martin Augustin, SR., Anke Muller, Lutz Zeitlmann, Andreas Marquardt, Michael A. Pleiss, Ulrich Heiser, Andre Johannes Niestroj
  • Inhibitors of Protein Kinases
    Publication number: 20150011576
    Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 8, 2015
    Inventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
  • Inhibitors of protein kinases
    Patent number: 8841315
    Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: September 23, 2014
    Assignee: AstraZeneca AB
    Inventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
  • Inhibitors of protein kinases
    Patent number: 8716296
    Abstract: Compounds of general formula (I): are useful as inhibitors of cyclin dependent kinases such as CDK9.
    Type: Grant
    Filed: October 13, 2008
    Date of Patent: May 6, 2014
    Assignee: Ingenium Pharmaceuticals GmbH
    Inventors: Hans Allgeier, Martin Augustin, Anke Müller, Lutz Zeitlmann, Andreas Marquardt, Michael A. Pleiss, Ulrich Heiser, André Johannes Niestroj
  • Use of 1H-Quinazoline-2,4-Diones
    Publication number: 20140018376
    Abstract: The invention concerns the use of competitive AMPA receptor antagonists for the treatment, prevention or delay of progression of Rasmussen's encephalitis and/or certain forms of epilepsy.
    Type: Application
    Filed: October 20, 2010
    Publication date: January 16, 2014
    Inventors: Hans Allgeier, Yves Auberson, Thomas Blaettler, David Carcache, Philipp Floersheim, Wolfgang Froestl, Christel Guibourdenche, Hans o Kalkman, Joerg Kallen, Manuel Koller, Kurt Lingenhohl, Henri Mattes, Joachim Nozulak, David Orain, Johanne Renaud, Christine Strohmaier
  • 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
    Publication number: 20130338147
    Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
    Type: Application
    Filed: August 12, 2013
    Publication date: December 19, 2013
    Applicant: Ingenium Pharmaceuticals GmbH
    Inventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Martin Augustin, Lutz Zeitlmann, Michael A. Pleiss, Gabriele Stumm, Anke Mueller, Axel Choidas, Bert Klebl, Gerhard Mueller, Wilfried Schwab, Joelle Le, Jackie Macritchie, Don Simpson
  • INHIBITORS OF PROTEIN KINASES
    Publication number: 20130331407
    Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
    Type: Application
    Filed: August 12, 2013
    Publication date: December 12, 2013
    Applicant: Ingenium Pharmaceuticals GmbH
    Inventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
  • 1H-QUINAZOLINE-2,4-DIONES
    Publication number: 20130296332
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Application
    Filed: July 1, 2013
    Publication date: November 7, 2013
    Inventors: Hans ALLGEIER, Yves AUBERSON, David CARCACHE, Philipp FLOERSHEIM, Christel GUIBOURDENCHE, Wolfgang FROESTL, Jörg KALLEN, Manuel KOLLER, Henri MATTES, Joachim NOZULAK, David ORAIN, Johanne RENAUD
  • NEUROTRYPSIN INHIBITORS
    Publication number: 20130261130
    Abstract: The invention relates to acylamino-phthalic acid amides and related compounds of formula (I) wherein A is —CON—R3R4, —NR5COR6, —NHR7, —OR8, —SR9, —CH2NR10R11, —(CH2)2-R12, —CH?CH—R12, —C?C—R12, optionally substituted phenyl, optionally substituted thiophenyl, or optionally substituted 1,2,3-triazol-4-yl, W is hydrogen, hydroxy or carboxymethoxy, Y is carboxy, methoxycarbonyl or 2H-tetrazol-5-yl, and the various substituents R have the meanings indicated in the description. These compounds are useful for the treatment and/or prophylaxis of skeletal muscle atrophy, schizophrenia and Alzheimer's disease, and as cognitive enhancers.
    Type: Application
    Filed: October 31, 2011
    Publication date: October 3, 2013
    Inventors: Shaheen Ahmed, Stefan Hettwer, Jan Willem Vrijbloed, Carlo Farina, Hans Allgeier
  • 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy
    Patent number: 8513268
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: August 20, 2013
    Assignee: Novartis AG
    Inventors: Hans Allgeier, Yves Auberson, David Carcache, Philipp Floersheim, Christel Guibourdenche, Wolfgang Froestl, Jörg Kallen, Manuel Koller, Henri Mattes, Joachim Nozulak, David Orain, Johanne Renaud
  • Inhibitors of protein kinases
    Patent number: 8507511
    Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases. formula (I).
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: August 13, 2013
    Assignee: Ingenium Pharmaceuticals GmbH
    Inventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
  • 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
    Patent number: 8507498
    Abstract: The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: August 13, 2013
    Assignee: Ingenium Pharmaceuticals GmbH
    Inventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Martin Augustin, Lutz Zeitlmann, Michael A. Pleiss, Gabriele Stumm, Anke Mueller, Axel Choidas, Bert Klebl, Gerhard Mueller, Wilfried Schwab, Joelle Le, Jackie Macritchie, Don Simpson
  • Inhibitors of protein kinases
    Patent number: 8436007
    Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: May 7, 2013
    Assignee: Ingenium Pharmaceuticals GmbH
    Inventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Martin Augustin, Lutz Zeitlmann, Michael A. Pleiss, Gabriele Stumm, Anke Mueller
  • Inhibitors of protein kinases
    Patent number: 8389521
    Abstract: The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceuticals compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases. formula (I).
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: March 5, 2013
    Assignee: Ingenium Pharmaceuticals GmbH
    Inventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
  • Quinazoline derivatives
    Patent number: 8299085
    Abstract: The present invention relates to 1H-Quinazoline-2,4-dione derivatives of formula(I) wherein the substituents are defined as in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: October 30, 2012
    Assignee: Novartis AG
    Inventors: Hans Allgeier, Wolfgang Froestl, Manuel Koller, Henri Mattes, Joachim Nozulak, Silvio Ofner, David Orain, Vittorio Rasetti, Johanne Renaud, Nicolas Soldermann, Philipp Floersheim
  • 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
    Publication number: 20110306602
    Abstract: The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.
    Type: Application
    Filed: April 24, 2008
    Publication date: December 15, 2011
    Inventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Lutz Zeitlmann, Anke Mueller, Martin Augustin, Michael A. Pleiss, Gabriele Stumm, Axel Choidas, Bert Klebl, Gerhard Mueller, Wilfried Schwab, Joelle Le, Jackie Macritchie, Don Simpson
  • 1H-QUINAZOLINE-2,4-DIONES
    Publication number: 20110294818
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Application
    Filed: July 28, 2011
    Publication date: December 1, 2011
    Inventors: Hans Allgeier, Yves Auberson, David Carcache, Philipp Floersheim, Christel Guibourdenche, Wolfgang Froestl, Jörg Kallen, Manuel Koller, Henri Mattes, Joachim Nozulak, David Orain, Johanne Renaud
  • N-(2,4-dioxo-6-(tetrahydrofuran-2-yl)-7-(trifluoromethyl)-1,4-dihydro-2H-quinazolin-3-yl)methanesulfonamide
    Patent number: 8012988
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: September 6, 2011
    Assignee: Novartis AG
    Inventors: Hans Allgeier, Yves Auberson, David Carcache, Philipp Floersheim, Christel Guibourdenche, Wolfgang Froestl, Jörg Kallen, Manuel Koller, Henri Mattes, Joachim Nozulak, David Orain, Johanne Renaud
  • Inhibitors of Protein Kinases
    Publication number: 20100249149
    Abstract: are useful as inhibitors of cyclin dependent kinases such as CDK9.
    Type: Application
    Filed: October 13, 2008
    Publication date: September 30, 2010
    Inventors: Hans Allgeier, Martin Augustin, Anke Müller, Luz Zeitlmann, Andreas Marquardt, Michael A. Pleiss, Ulrich Heiser, André Johannes Niestroj
  • INHIBITORS OF PROTEIN KINASES
    Publication number: 20100184789
    Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
    Type: Application
    Filed: April 24, 2008
    Publication date: July 22, 2010
    Inventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Martin Augustin, Lutz Zeitlmann, Michael A. Pleiss, Gabriele Stumm, Anke Mueller